Brought to you by 
Johnson & Johnson buys alliance partner Egea Biosciences
02 Jun 2004
Executive Summary
Johnson & Johnson has acquired Egea Biosciences, a biotech that has a platform for engineering and optimizing large-molecule therapeutic candidates and has been collaborating with J&J's Centocor subsidiary since last year. The earlier deal gave J&J the option to purchase its partner.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Johnson & Johnson buys alliance partner Egea Biosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice